Citigroup Inc Olema Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 30,097 shares of OLMA stock, worth $304,581. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,097

Previous 23,752 26.71%

Holding current value

$304,581

Previous $256,000 40.23%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$10.41 - $16.46 $66,051 - $104,438	6,345 Added 26.71%	30,097 $359,000
Q2 2024 Aug 12, 2024	SELL	$8.73 - $13.99 $1.97 Million - $3.16 Million	-226,230 Reduced 90.5%	23,752 $256,000
Q1 2024 May 10, 2024	BUY	$10.95 - $16.62 $2.68 Million - $4.07 Million	245,175 Added 5100.37%	249,982 $2.83 Million
Q4 2023 Feb 09, 2024	BUY	$10.53 - $17.14 $50,459 - $82,134	4,792 Added 31946.67%	4,807 $67,000
Q3 2023 Nov 09, 2023	SELL	$8.19 - $12.98 $65,348 - $103,567	-7,979 Reduced 99.81%	15 $0
Q2 2023 Aug 10, 2023	SELL	$3.22 - $9.65 $6,175 - $18,508	-1,918 Reduced 19.35%	7,994 $72,000
Q1 2023 May 11, 2023	BUY	$2.55 - $4.97 $25,275 - $49,262	9,912 New	9,912 $34,000
Q3 2022 Nov 10, 2022	SELL	$2.72 - $5.88 $1,267 - $2,740	-466 Reduced 28.04%	1,196 $3,000
Q2 2022 Aug 10, 2022	SELL	$2.04 - $4.61 $12,886 - $29,121	-6,317 Reduced 79.17%	1,662 $7,000
Q1 2022 May 12, 2022	SELL	$3.89 - $9.43 $1,124 - $2,725	-289 Reduced 3.5%	7,979 $34,000
Q4 2021 Feb 10, 2022	BUY	$8.75 - $30.71 $45,963 - $161,319	5,253 Added 174.23%	8,268 $77,000
Q3 2021 Nov 10, 2021	BUY	$22.96 - $30.13 $69,224 - $90,841	3,015 New	3,015 $83,000

Others Institutions Holding OLMA

# of Institutions

136

Shares Held

58.7M

Call Options Held

141K

Put Options Held

23.1K

View Full List

About Olema Pharmaceuticals, Inc.

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $409M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

More about OLMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account